Opus Genetics Secures Up To $155M Non-Dilutive Financing, Extends Runway to 2029
IRD has more than doubled off its 52-week low of $0.65 on light trading volume (0.4× avg).
Summary
Opus Genetics has secured a strategic financing agreement with Oberland Capital, providing access to up to $155 million in non-dilutive funding, including an initial $35 million tranche and a $5 million equity investment at $4.48 per share. This significant capital infusion, which builds upon the company's strengthened cash position noted in its recent 10-K, extends Opus Genetics' cash runway into 2029. The financing is crucial as it fully funds pivotal studies for OPGx-LCA5 and OPGx-BEST1, and enables the acceleration of three additional gene therapy programs (RDH12, MERTK, RHO) into clinical testing over the next year. This materially de-risks the company's development pipeline and enhances its long-term growth prospects, making it a highly positive development for investors. Traders should monitor the progress of these accelerated clinical programs and the achievement of milestones that unlock further tranches of the non-dilutive funding.
At the time of this announcement, IRD was trading at $4.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $323.7M. The 52-week trading range was $0.65 to $5.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.